| Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy JH Elliott, F Wightman, A Solomon, K Ghneim, J Ahlers, MJ Cameron, ... PLoS pathogens 10 (11), e1004473, 2014 | 553 | 2014 |
| Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study JH Elliott, JH McMahon, CC Chang, SA Lee, W Hartogensis, N Bumpus, ... The lancet HIV 2 (12), e520-e529, 2015 | 259 | 2015 |
| Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial SMART Study Group* Annals of internal medicine 149 (5), 289-299, 2008 | 167 | 2008 |
| Outcomes of treatment for hepatitis C in primary care, compared to hospital-based care: a randomized, controlled trial in people who inject drugs AJ Wade, JS Doyle, E Gane, C Stedman, B Draper, D Iser, SK Roberts, ... Clinical Infectious Diseases 70 (9), 1900-1906, 2020 | 94 | 2020 |
| Point-of-care hepatitis C testing from needle and syringe programs: an Australian feasibility study B Williams, J Howell, J Doyle, AJ Thompson, B Draper, C Layton, ... International Journal of Drug Policy 72, 91-98, 2019 | 51 | 2019 |
| Experiences and expectations of participants completing an HIV cure focused clinical trial JH McMahon, JH Elliott, J Roney, M Hagenauer, SR Lewin Aids 29 (2), 248-250, 2015 | 32 | 2015 |
| Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial JH McMahon, JSY Lau, A Coldham, J Roney, M Hagenauer, S Price, ... EClinicalMedicine 54, 2022 | 30 | 2022 |
| Microelimination of hepatitis C among people with human immunodeficiency virus coinfection: declining incidence and prevalence accompanying a multicenter treatment scale-up trial JS Doyle, DK van Santen, D Iser, J Sasadeusz, M O’Reilly, B Harney, ... Clinical Infectious Diseases 73 (7), e2164-e2172, 2021 | 26 | 2021 |
| Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV 2: e520–e529 JH Elliott, JH McMahon, CC Chang, SA Lee, W Hartogensis, N Bumpus, ... | 23 | 2015 |
| HealthMap: a cluster randomised trial of interactive health plans and self-management support to prevent coronary heart disease in people with HIV S Dodson, KM Klassen, K McDonald, T Millard, RH Osborne, ... BMC infectious diseases 16, 1-11, 2016 | 18 | 2016 |
| A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls JH McMahon, JM Zerbato, JSY Lau, JL Lange, M Roche, C Tumpach, ... EBioMedicine 65, 2021 | 16 | 2021 |
| The impact of point‐of‐care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian … J Howell, MW Traeger, B Williams, C Layton, JS Doyle, N Latham, ... Journal of viral hepatitis 29 (5), 375-384, 2022 | 13 | 2022 |
| No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy TM Mota, TA Rasmussen, A Rhodes, S Tennakoon, A Dantanarayana, ... AIDS 31 (8), 1137-1141, 2017 | 13 | 2017 |
| Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial AJ Wade, JS Doyle, E Gane, C Stedman, B Draper, D Iser, SK Roberts, ... Trials 19, 1-9, 2018 | 10 | 2018 |
| Micro-elimination of hepatitis C among people with HIV coinfection: declining incidence and prevalence accompanying a multi-center treatment scale-up trial JS Doyle, DK van Santen, D Iser, J Sasadeusz, M O’Reilly, B Harney Clin Infect Dis 3, 2020 | 8 | 2020 |
| Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count> or= 300 cells/microL who were assigned to 7.5 MIU interleukin-2. Z Fox, F Antunes, R Davey, B Gazzard, N Klimas, A Labriola, M Losso, ... HIV medicine 8 (2), 112-123, 2007 | 7 | 2007 |
| Trial of vancomycin and cefazolin as surgical prophylaxis in arthroplasty TN Peel, S Astbury, AC Cheng, DL Paterson, KL Buising, T Spelman, ... New England Journal of Medicine 389 (16), 1488-1498, 2023 | 6 | 2023 |
| Surveillance testing using salivary RT-PCR for SARS-CoV-2 in managed quarantine facilities in Australia: A laboratory validation and implementation study A Jenney, D Chibo, M Batty, J Druce, R Melvin, A Stewardson, ... The Lancet Regional Health–Western Pacific 26, 2022 | 5 | 2022 |
| An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial. JH McMahon, JSY Lau, J Roney, BA Rogers, J Trubiano, J Sasadeusz, ... Trials, 847-847, 2020 | 5 | 2020 |
| FRI-228-Community-based hepatitis C treatment of people who inject drugs and their injecting network is feasible and effective: Results from the TAP (Treatment And Prevention … J Doyle, P Dietze, M Stoove, P Higgs, P Desmond, D Iser, E Mcbryde, ... Journal of Hepatology 70 (1), e495, 2019 | 5 | 2019 |
